Clinical research has opened up avenues to evaluate the disease burden in the country. This is possible with the information coming in from clinical trials which helps map the disease prevalence in every area, expressed Dr. Denis Xavier, Chair, Scientific Committee, Eleventh National Conference and Vice Dean, St John’s Medical College.
Throughout the previous two decades, we didn’t know the disease burden in the country. There was no assessment of the disease regarding how much, what and where it showed.
Presently we have tried to examine this in spite of the fact that it isn’t and additionally the western world, yet an effort is made.
The application of computers enabled database age and availability of funding helped to undertake the clinical research, he included.
Dr. Denis in a media interaction at the ISCR 11th annual conference led in Bengaluru from January 19-20, 2018 expressed the implementation of balanced regulations for clinical trials has prompted confidence building and information generation other than increasing awareness that human study leads to new treatment options and novel drug prescription, other than creating a large pool of epidemiological information.
India represents one-fifth of the world’s disease burden and clinical research is a vital part of drug development. The developed countries represent 70 percent of the global clinical trials where US share is 41 percent and EU is 29 percent.
In any case, India holds a mere 1.2 percent and has a huge unmet therapeutic need. It is the rational regulatory changes in clinical trials by the central government which facilitated clinical research.
For the first time, India has state-level, fairly detailed or granular information on what is the disease, how much of it is there and where is it.
This is referred to as the Global Burden of Disease (GBD), a collaboration of more than 1,800 researchers from 127 countries.
Last November our government released a report titled ‘A Nation within a Nation’ which gives information on the heterogeneity of disease conditions in the country.
The information emanated from human studies directed by the pharma companies. In addition, Indian patients have participated in global clinical trials for cancer, cardiovascular diseases, diabetes, and infectious diseases. This includes observational studies and discovery of medicines.
Presently we have contributed key information to the Global Disease Burden yet need to improve this. This is the manner by which clinical research supports evaluation of disease burden in the country, said Dr. Xavier.